Literature DB >> 29939159

Enhancement of stem cell engraftment on a WHIM.

Hal E Broxmeyer.   

Abstract

WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a genetic autoimmune disorder that results from gain-of-function mutations in the gene encoding chemokine receptor CXCR4. A previous study characterized a patient with WHIM who underwent a chromothriptic event that resulted in spontaneous deletion of the WHIM allele in a single hematopoietic stem cell and subsequent cure of the disease. In this issue of the JCI, Gao et al. extend this work and show that Cxcl4-haplosufficient bone marrow has a selective advantage for long-term engraftment in murine WHIM models. Moreover, successful engraftment occurred without prior conditioning of recipients. Together, these results have important implications for improving hematopoietic stem/progenitor cell transplant not only for patients with WHIM but also for all patients who may require the procedure.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29939159      PMCID: PMC6063479          DOI: 10.1172/JCI121857

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  Chromothriptic cure of WHIM syndrome.

Authors:  David H McDermott; Ji-Liang Gao; Qian Liu; Marie Siwicki; Craig Martens; Paejonette Jacobs; Daniel Velez; Erin Yim; Christine R Bryke; Nancy Hsu; Zunyan Dai; Martha M Marquesen; Elina Stregevsky; Nana Kwatemaa; Narda Theobald; Debra A Long Priel; Stefania Pittaluga; Mark A Raffeld; Katherine R Calvo; Irina Maric; Ronan Desmond; Kevin L Holmes; Douglas B Kuhns; Karl Balabanian; Françoise Bachelerie; Stephen F Porcella; Harry L Malech; Philip M Murphy
Journal:  Cell       Date:  2015-02-05       Impact factor: 41.582

2.  Successful umbilical cord blood stem cell transplantation in a child with WHIM syndrome.

Authors:  Gergely Kriván; Melinda Erdos; Krisztián Kállay; Gábor Benyó; Agnes Tóth; János Sinkó; Vera Goda; Beáta Tóth; László Maródi
Journal:  Eur J Haematol       Date:  2009-10-29       Impact factor: 2.997

3.  Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells.

Authors:  Kent W Christopherson; Giao Hangoc; Hal E Broxmeyer
Journal:  J Immunol       Date:  2002-12-15       Impact factor: 5.422

4.  Combinations of antioxidants and/or of epigenetic enzyme inhibitors allow for enhanced collection of mouse bone marrow hematopoietic stem cells in ambient air.

Authors:  Qingchun Cai; Maegan Capitano; Xinxin Huang; Bin Guo; Scott Cooper; Hal E Broxmeyer
Journal:  Blood Cells Mol Dis       Date:  2018-02-13       Impact factor: 3.039

5.  Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.

Authors:  Michael M B Green; Nelson Chao; Saurabh Chhabra; Kelly Corbet; Cristina Gasparetto; Ari Horwitz; Zhiguo Li; Jagadish Kummetha Venkata; Gwynn Long; Alice Mims; David Rizzieri; Stefanie Sarantopoulos; Robert Stuart; Anthony D Sung; Keith M Sullivan; Luciano Costa; Mitchell Horwitz; Yubin Kang
Journal:  J Hematol Oncol       Date:  2016-08-17       Impact factor: 17.388

6.  Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis.

Authors:  Hal E Broxmeyer; Jonathan Hoggatt; Heather A O'Leary; Charlie Mantel; Brahmananda R Chitteti; Scott Cooper; Steven Messina-Graham; Giao Hangoc; Sherif Farag; Sara L Rohrabaugh; Xuan Ou; Jennifer Speth; Louis M Pelus; Edward F Srour; Timothy B Campbell
Journal:  Nat Med       Date:  2012-11-18       Impact factor: 53.440

7.  A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.

Authors:  David H McDermott; Qian Liu; Daniel Velez; Lizbeeth Lopez; Sandra Anaya-O'Brien; Jean Ulrick; Nana Kwatemaa; Judy Starling; Thomas A Fleisher; Debra A Long Priel; Melissa A Merideth; Robert L Giuntoli; Moses O Evbuomwan; Patricia Littel; Martha M Marquesen; Dianne Hilligoss; Rosamma DeCastro; George J Grimes; Samuel T Hwang; Stefania Pittaluga; Katherine R Calvo; Pamela Stratton; Edward W Cowen; Douglas B Kuhns; Harry L Malech; Philip M Murphy
Journal:  Blood       Date:  2014-02-12       Impact factor: 22.113

Review 8.  Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types.

Authors:  Xuan Ou; Heather A O'Leary; Hal E Broxmeyer
Journal:  Blood       Date:  2013-05-01       Impact factor: 22.113

9.  Cxcr4-haploinsufficient bone marrow transplantation corrects leukopenia in an unconditioned WHIM syndrome model.

Authors:  Ji-Liang Gao; Erin Yim; Marie Siwicki; Alexander Yang; Qian Liu; Ari Azani; Albert Owusu-Ansah; David H McDermott; Philip M Murphy
Journal:  J Clin Invest       Date:  2018-06-25       Impact factor: 14.808

Review 10.  Regulation of Chemokine Activity - A Focus on the Role of Dipeptidyl Peptidase IV/CD26.

Authors:  Mieke Metzemaekers; Jo Van Damme; Anneleen Mortier; Paul Proost
Journal:  Front Immunol       Date:  2016-11-11       Impact factor: 7.561

View more
  1 in total

1.  Mitigating oxygen stress enhances aged mouse hematopoietic stem cell numbers and function.

Authors:  Maegan L Capitano; Safa F Mohamad; Scott Cooper; Bin Guo; Xinxin Huang; Andrea M Gunawan; Carol Sampson; James Ropa; Edward F Srour; Christie M Orschell; Hal E Broxmeyer
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.